Antengene Corporation Ltd
HKEX:6996
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Antengene Corporation Ltd
Total Liabilities & Equity
Antengene Corporation Ltd
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Antengene Corporation Ltd
HKEX:6996
|
Total Liabilities & Equity
¥1.3B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Total Liabilities & Equity
¥39.9B
|
CAGR 3-Years
10%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Total Liabilities & Equity
¥69.9B
|
CAGR 3-Years
18%
|
CAGR 5-Years
15%
|
CAGR 10-Years
20%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Total Liabilities & Equity
¥54.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
11%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Total Liabilities & Equity
¥45.6B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
17%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Total Liabilities & Equity
¥7.1B
|
CAGR 3-Years
96%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
|
Antengene Corporation Ltd
Glance View
Antengene Corp. Ltd. operates as clinical-stage Asia-Pacific biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-20. The firm is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company’s products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The firm mainly conducts its business in Asia-Pacific.
See Also
What is Antengene Corporation Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
1.3B
CNY
Based on the financial report for Dec 31, 2025, Antengene Corporation Ltd's Total Liabilities & Equity amounts to 1.3B CNY.
What is Antengene Corporation Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
-17%
Over the last year, the Total Liabilities & Equity growth was -7%. The average annual Total Liabilities & Equity growth rates for Antengene Corporation Ltd have been -16% over the past three years , -17% over the past five years .
